Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

EU regulator launches real-time review of AstraZeneca's COVID-19 vaccine

Published 01/10/2020, 14:09
Updated 01/10/2020, 14:25
© Reuters. A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken

© Reuters. A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken

(Reuters) - The European health regulator said on Thursday it had started a rolling review of the experimental COVID-19 vaccine from AstraZeneca (L:AZN) and Oxford University, in a move aimed at speeding up any future approval process.

The European Medicines Agency (EMA) said its human medicines committee had started evaluating the first batch of data on the vaccine, and will continue till sufficient data is available and a formal application is submitted. (https://

The news raises the chances of the vaccine being the first to be approved in the region, and comes just weeks after several global trials of the vaccine were halted due to an unexplained illness in a study participant.

U.S. trials are still under review, with regulators widening their probe, Reuters reported on Wednesday.

"This (EMA's review) does not mean that a conclusion can be reached yet on the vaccine's safety and effectiveness, as much of the evidence is still to be submitted to the committee," the watchdog said.

Early-stage data in July showed the vaccine elicited immune responses in clinical trials and produced no serious side effects, with the strongest response seen in people who received two doses. Data on late-stage trials are expected soon.

The EMA would make final recommendations, once the review is completed, to the European Commission, which has the ultimate say over approvals. The commission typically follows EMA endorsements.

The EMA began a similar real-time review of Gilead's (O:GILD) Veklury as a treatment for COVID-19 earlier this year, and the antiviral treatment was given conditional approval for use just months later in July.

© Reuters. A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.